<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Fragile X syndrome: Management in children and adolescents
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Fragile X syndrome: Management in children and adolescents
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Fragile X syndrome: Management in children and adolescents
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Author:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Hilde Van Esch, MD, PhD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Helen V Firth, DM, FRCP, FMedSci
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Robert G Voigt, MD, FAAP
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Elizabeth TePas, MD, MS
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Dec 12, 2023.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H1">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         The management of children and adolescents with fragile X syndrome (FXS) is individualized according to the child's cognitive and behavioral symptoms, strengths, and weaknesses [
         <a href="#rid1">
          1,2
         </a>
         ]. (See
         <a class="local">
          'Evaluation to determine extent of disease'
         </a>
         below.)
        </p>
        <p>
         Interventions may include individualized education programs, speech and language therapy, occupational therapy, behavior therapy, and pharmacotherapy. Few controlled trials have been performed to assess the effectiveness of these interventions in children with FXS [
         <a href="#rid3">
          3,4
         </a>
         ]. However, they are effective in children with other cognitive or behavioral problems. (See
         <a class="medical medical_review" href="/z/d/html/6191.html" rel="external">
          "Intellectual disability (ID) in children: Management, outcomes, and prevention"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/614.html" rel="external">
          "Specific learning disorders in children: Educational management"
         </a>
         .)
        </p>
        <p>
         The management of children and adolescents with FXS is discussed in this topic review. The clinical features, diagnosis, and prenatal screening are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/2924.html" rel="external">
          "Fragile X syndrome: Clinical features and diagnosis in children and adolescents"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/437.html" rel="external">
          "Fragile X syndrome: Prenatal screening and diagnosis"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3">
         <span class="h1">
          GENETIC COUNSELING
         </span>
         <span class="headingEndMark">
          —
         </span>
         Families of persons with FXS should be referred to a geneticist or genetic counselor for a detailed discussion of the inheritance of a fragile X messenger ribonucleoprotein 1 (
         <em>
          FMR1
         </em>
         ) mutation and testing of other family members. FXS test results should be interpreted for the family according to the guidelines established by the National Society of Genetic Counselors and the American Society of Human Genetics [
         <a href="#rid2">
          2,5
         </a>
         ]. Family members at risk for premutation or full mutation of
         <em>
          FMR1
         </em>
         should receive information about possible emotional, neurologic, and reproductive problems (eg, premature ovarian insufficiency).
        </p>
        <p class="headingAnchor" id="H1154182401">
         <span class="h1">
          EVALUATION TO DETERMINE EXTENT OF DISEASE
         </span>
         <span class="headingEndMark">
          —
         </span>
         Following initial diagnosis of FXS, children and adolescents should undergo a multidisciplinary evaluation to determine the extent of disease [
         <a href="#rid1">
          1
         </a>
         ]. The evaluation should include:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Complete developmental and educational assessments (including speech and language, academic, problem solving skills using visual information, fine motor, and gross motor) for special educational planning.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Behavioral and psychology assessment to evaluate cognitive abilities, adaptive behavior, concentration or attention problems, anxiety, obsessive compulsive symptoms, aggression, and depression.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Medical evaluation for presence of associated medical problems, including feeding problems, gastroesophageal reflux, hypotonia, joint laxity, mitral valve prolapse, seizures, strabismus, and recurrent otitis media. (See
         <a class="medical medical_review" href="/z/d/html/2924.html" rel="external">
          "Fragile X syndrome: Clinical features and diagnosis in children and adolescents", section on 'Additional associated findings'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/2924.html" rel="external">
          "Fragile X syndrome: Clinical features and diagnosis in children and adolescents", section on 'Seizures'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H4">
         <span class="h1">
          DEVELOPMENTAL AND EDUCATIONAL INTERVENTIONS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Children and adolescents with FXS usually have special educational needs and should be referred for early intervention (if less than 36 months of age) or special educational (if greater than 36 months of age) programs [
         <a href="#rid6">
          6,7
         </a>
         ]. Children with FXS often have difficulties with mathematics and expressive language skills [
         <a href="#rid8">
          8
         </a>
         ]. However, developmental strengths and weaknesses must be assessed on an individual basis [
         <a href="#rid7">
          7
         </a>
         ]. Children with FXS and autism require additional educational interventions. The
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Ffragilex.org%2F&amp;token=T5M9GKYlNl%2BZvkR9N5GxcphyL9KBPQKWKx8XOK6A184%3D&amp;TOPIC_ID=2925" target="_blank">
          National Fragile X Foundation website
         </a>
         contains detailed information in several languages on the recommended educational programs for children with FXS that can be downloaded. In addition, the use and efficacy of tablet-based cognitive and working memory training programs are under investigation in persons with FXS [
         <a href="#rid9">
          9
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/2924.html" rel="external">
          "Fragile X syndrome: Clinical features and diagnosis in children and adolescents"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H5">
         <span class="h1">
          BEHAVIORAL INTERVENTIONS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Behavioral interventions may be effective in promoting coping skills and reducing problematic behaviors (eg, aggression, stereotypic behaviors, self-injury) [
         <a href="#rid7">
          7,10,11
         </a>
         ]. There are few empirical studies of the effectiveness of behavioral interventions for children and adolescents with FXS [
         <a href="#rid12">
          12
         </a>
         ]. Treatment strategies are guided by the therapist's experience and understanding of factors associated with problematic behaviors [
         <a href="#rid7">
          7,12
         </a>
         ]. These behaviors often are precipitated and reinforced by social and/or environmental events (eg, anxiety, sensory overload, change in routine, the amount of attention the child is receiving, etc) [
         <a href="#rid7">
          7,13-16
         </a>
         ]. Environmental changes (eg, small class size, avoiding excessive stimulation, avoiding sudden changes) may reduce the frequency of problem behaviors [
         <a href="#rid1">
          1,17
         </a>
         ]. In addition, individuals with FXS can be taught to recognize stressful situations and use self-calming techniques before responding inappropriately [
         <a href="#rid7">
          7
         </a>
         ].
        </p>
        <p>
         Behavioral interventions for children with intellectual disability and autism spectrum disorder are discussed in greater detail separately. (See
         <a class="medical medical_review" href="/z/d/html/6191.html" rel="external">
          "Intellectual disability (ID) in children: Management, outcomes, and prevention", section on 'Behavior intervention'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/607.html" rel="external">
          "Autism spectrum disorder in children and adolescents: Behavioral and educational interventions"
         </a>
         .)
        </p>
        <p>
         Children and adolescents with FXS who have higher levels of function may benefit from counseling or psychotherapy to focus on anxiety reduction, socialization, and depression [
         <a href="#rid12">
          12,18
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H10">
         <span class="h1">
          PHARMACOTHERAPY
         </span>
         <span class="headingEndMark">
          —
         </span>
         Psychopharmacologic therapy may be necessary for children and adolescents with FXS and attention deficit hyperactivity disorder, anxiety, mood instability, or maladaptive behaviors (eg, perseveration, aggression, self-injury) that significantly affect social interaction and are not controlled with environmental or behavioral interventions. There is no specific therapy for enhancing cognitive abilities [
         <a href="#rid4">
          4
         </a>
         ].
        </p>
        <p>
         Psychopharmacologic intervention is individualized according to symptoms and must be closely monitored [
         <a href="#rid1">
          1
         </a>
         ]. Specific agents may help with some problematic behaviors but exacerbate others [
         <a href="#rid4">
          4
         </a>
         ].
        </p>
        <p>
         There are few controlled studies evaluating the use of psychopharmacologic interventions in children and adolescents with FXS. Evidence to support their use is derived from observational surveys of clinical populations [
         <a href="#rid12">
          12
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H12">
         <span class="h2">
          Hyperactivity and inattention
         </span>
         <span class="headingEndMark">
          —
         </span>
         Inattention and hyperactivity in children with FXS over five years of age are typically treated with stimulants [
         <a href="#rid4">
          4
         </a>
         ]. Observational studies suggest that stimulants are beneficial in approximately 70 percent of boys with FXS [
         <a href="#rid4">
          4,19
         </a>
         ]. In a small, placebo-controlled crossover trial,
         <a class="drug drug_pediatric" data-topicid="12600" href="/z/d/drug information/12600.html" rel="external">
          methylphenidate
         </a>
         in addition to behavioral interventions and individualized therapy was associated with improved teacher ratings of socialization skills and attention span [
         <a href="#rid19">
          19
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/16927.html" rel="external">
          "Attention deficit hyperactivity disorder in children and adolescents: Treatment with medications"
         </a>
         .)
        </p>
        <p>
         Benefits of stimulants may include increased attention span and decreased distractibility, motor activity, fidgeting, and impulsivity [
         <a href="#rid4">
          4
         </a>
         ]. Adverse effects of stimulants may include appetite suppression, insomnia, moodiness, increased aggressiveness or irritability, and aggravation of anxiety or perseveration. (See
         <a class="medical medical_review" href="/z/d/html/621.html" rel="external">
          "Pharmacology of drugs used to treat attention deficit hyperactivity disorder in children and adolescents", section on 'Stimulant adverse effects'
         </a>
         .)
        </p>
        <p>
         In children younger than five years, stimulants may exacerbate irritability or other behavior problems. Nonstimulant therapies (eg, alpha-2 agonists such as
         <a class="drug drug_pediatric" data-topicid="15555" href="/z/d/drug information/15555.html" rel="external">
          guanfacine
         </a>
         and
         <a class="drug drug_pediatric" data-topicid="13171" href="/z/d/drug information/13171.html" rel="external">
          clonidine
         </a>
         ) often are used in this age group to treat hyperactivity, inattention, and hyperarousal [
         <a href="#rid4">
          4,12
         </a>
         ]. In observational studies, alpha-2 agonists are beneficial in approximately 60 to 70 percent of patients [
         <a href="#rid4">
          4,20,21
         </a>
         ]. Adverse effects of alpha-2 agonists include decreased blood pressure and sedation [
         <a href="#rid20">
          20
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/16927.html" rel="external">
          "Attention deficit hyperactivity disorder in children and adolescents: Treatment with medications"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H13">
         <span class="h2">
          Other behaviors
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Anxiety, compulsive behaviors, and mood symptoms
         </strong>
         may be managed with antidepressants, such as selective serotonin reuptake inhibitors (SSRIs). Observational studies suggest that treatment with SSRIs relieves anxiety in approximately 50 percent of patients with FXS [
         <a href="#rid4">
          4,22
         </a>
         ]. However, approximately 20 percent of treated patients reported activation (restlessness, mood change, disinhibited behavior, aggression) with SSRIs [
         <a href="#rid22">
          22
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/15928.html" rel="external">
          "Pharmacotherapy for anxiety disorders in children and adolescents", section on 'SSRI/SNRI'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Benefits of SSRIs may include decreased obsessive-compulsive behaviors, decreased irritability, increased comfort in social situations, and ability to tolerate environmental stimuli [
         <a href="#rid4">
          4
         </a>
         ]. Adverse effects may include activation, changes in appetite, insomnia, nausea, and suicidal ideation. (See
         <a class="medical medical_review" href="/z/d/html/1227.html" rel="external">
          "Pediatric unipolar depression and pharmacotherapy: Choosing a medication", section on 'Adverse side effects'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Irritability, aggression, mood instability, and perseverative behaviors
         </strong>
         may respond to treatment with antipsychotic agents (eg,
         <a class="drug drug_pediatric" data-topicid="12770" href="/z/d/drug information/12770.html" rel="external">
          risperidone
         </a>
         ,
         <a class="drug drug_pediatric" data-topicid="13180" href="/z/d/drug information/13180.html" rel="external">
          aripiprazole
         </a>
         ) [
         <a href="#rid4">
          4,12
         </a>
         ]. In controlled trials in children with autism, risperidone has been shown to be beneficial in controlling aggressive and aberrant behavior [
         <a href="#rid23">
          23-25
         </a>
         ], and it is US Food and Drug Administration (FDA) approved for use in children above five years of age. Aripiprazole, which is US FDA approved for children over six years of age, also may target distractibility, anxiety, mood instability, and aberrant social behaviors.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Benefits of antipsychotics may include improved sleep and decreased anxiety, agitation, perseveration, and aggression [
         <a href="#rid4">
          4
         </a>
         ]. Adverse effects may include sedation, nausea, constipation, dystonic and extrapyramidal reactions, gynecomastia, and weight gain [
         <a href="#rid26">
          26
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/603.html" rel="external">
          "Autism spectrum disorder in children and adolescents: Pharmacologic interventions"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H14">
         <span class="h2">
          Seizures
         </span>
         <span class="headingEndMark">
          —
         </span>
         Seizures in children with FXS generally are controlled with a single antiseizure medication (eg,
         <a class="drug drug_pediatric" data-topicid="13113" href="/z/d/drug information/13113.html" rel="external">
          carbamazepine
         </a>
         , valproate [
         <a class="drug drug_pediatric" data-topicid="12873" href="/z/d/drug information/12873.html" rel="external">
          valproic acid
         </a>
         ],
         <a class="drug drug_pediatric" data-topicid="12542" href="/z/d/drug information/12542.html" rel="external">
          lamotrigine
         </a>
         ,
         <a class="drug drug_pediatric" data-topicid="12664" href="/z/d/drug information/12664.html" rel="external">
          oxcarbazepine
         </a>
         ,
         <a class="drug drug_pediatric" data-topicid="12612" href="/z/d/drug information/12612.html" rel="external">
          zonisamide
         </a>
         ) [
         <a href="#rid12">
          12
         </a>
         ]. Valproate also works as a mood stabilizer and can help with aggression or episodic dyscontrol in some children [
         <a href="#rid27">
          27
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/6203.html" rel="external">
          "Seizures and epilepsy in children: Initial treatment and monitoring"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/2221.html" rel="external">
          "Antiseizure medications: Mechanism of action, pharmacology, and adverse effects"
         </a>
         .)
        </p>
        <p>
         <a class="drug drug_pediatric" data-topicid="12702" href="/z/d/drug information/12702.html" rel="external">
          Phenytoin
         </a>
         is usually avoided because it is associated with gingival hypertrophy, and it is difficult to manage dental problems in children with FXS because of their hypersensitivity.
         <a class="drug drug_pediatric" data-topicid="12698" href="/z/d/drug information/12698.html" rel="external">
          Phenobarbital
         </a>
         and
         <a class="drug drug_pediatric" data-topicid="13330" href="/z/d/drug information/13330.html" rel="external">
          gabapentin
         </a>
         may exacerbate behavior problems and also should be avoided in children with FXS.
        </p>
        <p class="headingAnchor" id="H15">
         <span class="h2">
          Investigational therapies
         </span>
         <span class="headingEndMark">
          —
         </span>
         A number of investigational therapies target biochemical pathways that are thought to play a role in the clinical manifestations of FXS [
         <a href="#rid28">
          28
         </a>
         ], but the evidence for each of these therapies is at best weak or marginal. These therapies include:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Metabotropic glutamate receptor 5 (mGluR5) antagonists
         </strong>
         – Excessive mGluR5 signaling is thought to contribute to some of the behavioral abnormalities and cognitive deficits of FXS [
         <a href="#rid3">
          3,12,29
         </a>
         ]. In animal models, mGluR5 antagonists have demonstrated improvements in behavior and cognition; reduction of anxiety, depression, and seizures; and correction of underlying abnormal cellular processes such as aberrant cell signaling [
         <a href="#rid3">
          3,30-32
         </a>
         ]. A small, randomized trial in 30 adult patients with FXS showed significant improvement on the Aberrant Behavior Checklist-Community Edition (ABC-C) score but only in the subset of seven patients with a fully methylated promoter [
         <a href="#rid33">
          33,34
         </a>
         ]. Additional studies investigating the effect of mGluR5 antagonists on language learning also failed to show any significant result in three to six year-old children with FXS [
         <a href="#rid35">
          35
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Lithium
         </strong>
         <strong>
         </strong>
         –
         <a class="drug drug_pediatric" data-topicid="12559" href="/z/d/drug information/12559.html" rel="external">
          Lithium
         </a>
         downregulates the phospholipase C signaling pathway that is used by mGluR5 and other receptors to activate dendritic translation, and it has the potential to correct excessive dendritic protein synthesis in FXS [
         <a href="#rid12">
          12
         </a>
         ]. A small, open-labeled trial of lithium in 15 males with FXS (6 to 23 years) found significant improvement in behavioral functioning, adaptive behavior, and verbal memory [
         <a href="#rid36">
          36
         </a>
         ]. Larger randomized trials are needed to confirm these results.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Minocycline
         </strong>
         – Matrix metalloproteinases (MMP) modulate synaptic physiology and plasticity, and MMP9 levels are elevated in the hippocampus in patients with FXS [
         <a href="#rid37">
          37
         </a>
         ]. Open-label studies of
         <a class="drug drug_pediatric" data-topicid="12915" href="/z/d/drug information/12915.html" rel="external">
          minocycline
         </a>
         in patients with FXS demonstrated improvements in language, attention, social communication, anxiety, and behavior [
         <a href="#rid38">
          38,39
         </a>
         ]. A subsequent randomized trial of minocycline in 55 individuals (aged 3.5 to 16 years) showed improvement on the Clinical Global Impression Scale [
         <a href="#rid40">
          40
         </a>
         ]. Another clinical trial in which minocycline was combined with
         <a class="drug drug_pediatric" data-topicid="12566" href="/z/d/drug information/12566.html" rel="external">
          lovastatin
         </a>
         in 22 persons showed significant improvement in the ABC-C global score [
         <a href="#rid41">
          41
         </a>
         ]. However, the potential benefits of this therapy should be weighed against the potential side effects of prolonged intake of antibiotics, including diarrhea and discoloration of the teeth in young infants, especially in children, who would require long-term treatment. In addition, minocycline treatment can increase antinuclear antibody levels, which can cause a lupus-like syndrome. This effect is reversed when minocycline is discontinued [
         <a href="#rid37">
          37
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Gamma-aminobutyric acid (GABA) system agonists
         </strong>
         – GABA is the primary inhibitory neurotransmitter in the central nervous system. The GABA system is downregulated in FXS [
         <a href="#rid42">
          42
         </a>
         ]. Social function and behavior, but not irritability, improved in patients with FXS in a phase II trial of the GABA agonist arbaclofen [
         <a href="#rid43">
          43
         </a>
         ]. In two subsequent phase III trials, adolescents and adults with FXS who received arbaclofen did not show behavioral improvement compared with patients who received placebo, but children 5 to 11 years of age had a significant improvement on the Aberrant Behavior Checklist-Community Edition (ABC-CFX) [
         <a href="#rid44">
          44
         </a>
         ]. A subsequent phase II study with
         <a class="drug drug_pediatric" data-topicid="135302" href="/z/d/drug information/135302.html" rel="external">
          ganaxolone
         </a>
         , a GABA-A receptor agonist, did not show significant improvements in the outcome measures in the overall study population (6 to 17 years).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Chloride importer antagonists
         </strong>
         – As noted above, GABAergic signaling is deficient in FXS [
         <a href="#rid42">
          42
         </a>
         ]. However, GABA actions are shifted from inhibitory to excitatory with elevated levels of intracellular chloride seen in many disorders, including FXS.
         <a class="drug drug_pediatric" data-topicid="13097" href="/z/d/drug information/13097.html" rel="external">
          Bumetanide
         </a>
         , a diuretic NKCC1 chloride importer antagonist that decreases intracellular chloride and has shown efficacy in treating autism, improved autistic features in a patient with FXS [
         <a href="#rid45">
          45
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          L-acetylcarnitine (LAC)
         </strong>
         – LAC, the acetylated form of carnitine, inhibits expression of the FXS-associated fragile site, FRAXA [
         <a href="#rid46">
          46
         </a>
         ]. Two small, randomized trials have examined the efficacy of LAC in treating the psychological, learning, behavioral (eg, hyperactivity), and socialization problems in patients with FXS and essentially found no differences compared with placebo [
         <a href="#rid47">
          47
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Ampakines (positive AMPA receptor modulators)
         </strong>
         – Excessive mGluR activity contributes to reduced synaptic alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) and excessive internalization of AMPA receptors [
         <a href="#rid12">
          12
         </a>
         ]. Reduced AMPA receptor signaling is another potential target for therapy. In a controlled trial, treatment with CX516 (an ampakine) had no effect on cognitive function in a cohort of subjects with FXS [
         <a href="#rid48">
          48
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Cannabinoid receptor antagonists
         </strong>
         – Activation of mGluR5 enhances production of endocannabinoids, leading to depression of excitatory and inhibitory transmission and amplification of the mammalian (mechanistic) target of rapamycin (mTOR) signaling pathway mediated via cannabinoid receptor 1 (CNR1, also called CB1R). In a mouse model, CNR1 blockade with rimonabant normalized cognitive performance, nociception, and seizure susceptibility [
         <a href="#rid49">
          49
         </a>
         ]. A phase III trial, using a transdermal cannabidiol gel, demonstrated some benefits in patients with full methylation of the
         <em>
          FMR1
         </em>
         gene [
         <a href="#rid50">
          50
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          mTOR inhibitors
         </strong>
         – Enhanced mTOR signaling is thought to contribute to some of the cognitive deficits seen in patients with FXS [
         <a href="#rid51">
          51
         </a>
         ]. Both acute and chronic administration of an mTOR inhibitor,
         <a class="drug drug_general" data-topicid="10344" href="/z/d/drug information/10344.html" rel="external">
          temsirolimus
         </a>
         , prevented memory impairment in a murine model [
         <a href="#rid49">
          49
         </a>
         ].
        </p>
        <p>
        </p>
        <p>
         In addition to pharmacologic investigational therapies that target biochemical pathways, other therapeutic avenues using cellular and animal models are under exploration:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Since FXS is the result of silencing of the
         <em>
          FMR1
         </em>
         gene due to hypermethylation of the CGG expansion mutation, reactivation by targeted deoxyribonucleic acid (DNA) demethylation of the CGG expansion is a possible therapeutic strategy. Preliminary efforts in stem cells and even in postmitotic FXS neurons in vitro show encouraging data [
         <a href="#rid52">
          52
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Other strategies are exploring possible excision of the CGG expansion using the novel CrispR/Cas9 technology. Initial results, performed in induced pluripotent stem cells derived from patients with FXS, show that this is possible, albeit with low efficiency [
         <a href="#rid53">
          53
         </a>
         ]. Another approach to excise the expansion involving the endogenous DNA repair machinery is under investigation [
         <a href="#rid54">
          54
         </a>
         ]. The use of antisense oligonucleotides is also being explored as a possible therapeutic avenue [
         <a href="#rid55">
          55
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3324835224">
         <span class="h1">
          HEALTH SUPERVISION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Children and adolescents with FXS should receive routine health supervision and prompt referral for medical, therapeutic, educational, and consultative services (eg, early intervention services, speech therapy) [
         <a href="#rid2">
          2,7,56
         </a>
         ].
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fpublications.aap.org%2Fpediatrics%2Farticle%2F127%2F5%2F994%2F64903%2FHealth-Supervision-for-Children-With-Fragile-X&amp;token=g1wn%2FsYukzeDrkfA1YDukcEZ3eeAvEAso%2FhODIzOeNymBcSzg%2BJMkjlMyYuQJeMSigT4Bh1rRLyR9Jg8RanGvMUkxE2P6DamMWrL%2FZP0ACnWHZFlm7TSj2vOxx5cCPP7ubyYQlxsjToDnSOFPDeodA%3D%3D&amp;TOPIC_ID=2925" target="_blank">
          Health supervision guidelines
         </a>
         from the American Academy of Pediatrics Committee on Genetics are available online.
        </p>
        <p class="headingAnchor" id="H2630962891">
         <span class="h2">
          Support
         </span>
         <span class="headingEndMark">
          —
         </span>
         Families with fragile X mutation or premutation benefit from parental and social supports [
         <a href="#rid7">
          7
         </a>
         ]. Personal and family support should be reviewed at regularly scheduled health supervision visits [
         <a href="#rid6">
          6
         </a>
         ]. Internet-based information and support resources are provided below. (See
         <a class="local">
          'Resources'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H2411423504">
         <span class="h2">
          Surveillance
         </span>
         <span class="headingEndMark">
          —
         </span>
         In addition to intellectual disability and language and behavior problems, children and adolescents with FXS are at risk for a number of medical problems. Surveillance for these problems and appropriate intervention and/or referral should occur at regularly scheduled health maintenance visits throughout childhood, adolescence, and young adulthood [
         <a href="#rid6">
          6
         </a>
         ].
        </p>
        <p>
         Associated medical concerns in children and adolescents with FXS include [
         <a href="#rid6">
          6,13,57
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Flat feet (80 percent) and other connective tissue manifestations (eg, ligamentous laxity, inguinal hernia) [
         <a href="#rid57">
          57,58
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/6521.html" rel="external">
          "Forefoot and midfoot pain in the active child or skeletally immature adolescent: Overview of causes", section on 'Flexible pes planus (flat feet)'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/6476.html" rel="external">
          "Inguinal hernia in children"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Gastroesophageal reflux. (See
         <a class="medical medical_review" href="/z/d/html/5876.html" rel="external">
          "Gastroesophageal reflux in infants"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/5892.html" rel="external">
          "Clinical manifestations and diagnosis of gastroesophageal reflux disease in children and adolescents"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Mitral valve prolapse (typically develops during adolescence or adulthood; present in 50 percent of adults) [
         <a href="#rid57">
          57
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/8172.html" rel="external">
          "Mitral valve prolapse: Clinical manifestations and diagnosis"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Recurrent otitis media (60 percent) [
         <a href="#rid57">
          57,59
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/6021.html" rel="external">
          "Acute otitis media in children: Epidemiology, microbiology, and complications"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/6009.html" rel="external">
          "Acute otitis media in children: Clinical manifestations and diagnosis"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Macro-orchidism, hernias, and varicoceles. Macro-orchidism usually starts to develop at approximately nine years of age, and the testes size increases throughout puberty (mean testicular volume in adulthood: approximately 50 mL). Boys and adult males with a full mutation should be assessed for the presence of hernia or varicocele.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Refractive errors (20 percent), strabismus (8 to 30 percent), and nystagmus [
         <a href="#rid57">
          57
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/6260.html" rel="external">
          "Refractive errors in children"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/6269.html" rel="external">
          "Evaluation and management of strabismus in children", section on 'Evaluation'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Seizures (as many as 20 percent) [
         <a href="#rid60">
          60-62
         </a>
         ]. The peak incidence is between six months and four years of age [
         <a href="#rid12">
          12,61,62
         </a>
         ]. The possibility of seizures should be considered in older children and adolescents if school performance is declining or when a disturbed sleep pattern occurs. (See
         <a class="medical medical_review" href="/z/d/html/6218.html" rel="external">
          "Seizures and epilepsy in children: Clinical and laboratory diagnosis"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Scoliosis (&lt;20 percent) [
         <a href="#rid57">
          57
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/6286.html" rel="external">
          "Adolescent idiopathic scoliosis: Clinical features, evaluation, and diagnosis"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/6291.html" rel="external">
          "Adolescent idiopathic scoliosis: Management and prognosis"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Depression [
         <a href="#rid13">
          13
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/1224.html" rel="external">
          "Pediatric unipolar depression: Epidemiology, clinical features, assessment, and diagnosis"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/1231.html" rel="external">
          "Overview of prevention and treatment for pediatric depression"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Anxiety [
         <a href="#rid13">
          13
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/15926.html" rel="external">
          "Anxiety disorders in children and adolescents: Epidemiology, pathogenesis, clinical manifestations, and course"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/15928.html" rel="external">
          "Pharmacotherapy for anxiety disorders in children and adolescents"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/15927.html" rel="external">
          "Psychotherapy for anxiety disorders in children and adolescents"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2500685662">
         <span class="h2">
          Anticipatory guidance
         </span>
         <span class="headingEndMark">
          —
         </span>
         The American Academy of Pediatrics guidelines for health supervision of children with FXS suggest providing anticipatory guidance according to the following schedule [
         <a href="#rid2">
          2
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Birth to one month
         </strong>
         – Infants in this age group generally are identified through prenatal testing because of a positive family history. Review support groups and available services. Discuss how and what to tell family members and friends [
         <a href="#rid63">
          63
         </a>
         ]. Review the recurrence risk for subsequent pregnancies; discuss options for family planning, including prenatal and preimplantation genetic testing. Review the family history regarding evaluation of other family members at risk of having a premutation or full mutation, or refer for formal genetic counseling to address these issues.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          One month to one year
         </strong>
         – Discuss irritability and tantrums. Refer for early intervention services (in the United States).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          One to five years
         </strong>
         – Review the preschool program. Refer for speech and language therapy, physical therapy, and occupational therapy as indicated. Formal developmental evaluation may be warranted. There is no formal recommendation for when the developmental, educational (including speech and language), behavioral, and psychological assessments should take place. At the author's center, a complete assessment is performed at two and approximately four years of age.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Five to 13 years
         </strong>
         – Assess effectiveness of behavioral interventions. Discuss how parents/caregivers and siblings address behavioral problems. Review development and appropriateness of school placement (eg, visual presentation of information, small classroom size, individualized attention, speech and language therapy, occupational therapy). (See
         <a class="local">
          'Developmental and educational interventions'
         </a>
         above and
         <a class="local">
          'Behavioral interventions'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Thirteen to 21 years
         </strong>
         – Review behavioral concerns (eg, violent outbursts). Assess psychosocial development, physical and sexual development, and fertility. Discuss the need for and level of supervision, and discuss the need for birth control. The
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Ffragilex.org%2F&amp;token=T5M9GKYlNl%2BZvkR9N5GxcphyL9KBPQKWKx8XOK6A184%3D&amp;TOPIC_ID=2925" target="_blank">
          National Fragile X Foundation
         </a>
         provides resources for discussing sexuality with children and adolescents with FXS. Discuss the need for vocational training and group home placement, if appropriate. Facilitate transition to adult medical care as appropriate or desired.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H16">
         <span class="h1">
          PRADER-WILLI PHENOTYPE
         </span>
         <span class="headingEndMark">
          —
         </span>
         Treatment of children with the Prader-Willi phenotype of FXS is similar to that for children with Prader-Willi syndrome without FXS. (See
         <a class="medical medical_review" href="/z/d/html/5864.html" rel="external">
          "Prader-Willi syndrome: Management", section on 'Recombinant growth hormone treatment'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/5864.html" rel="external">
          "Prader-Willi syndrome: Management", section on 'Feeding and obesity'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/5864.html" rel="external">
          "Prader-Willi syndrome: Management"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H17">
         <span class="h1">
          PROGNOSIS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Life expectancy for individuals with FXS is normal [
         <a href="#rid7">
          7
         </a>
         ]. Adult males typically have an intelligence quotient (IQ) in the moderate intellectual disability range (the average IQ in adult males with a completely methylated full mutation is approximately 40) [
         <a href="#rid3">
          3,64
         </a>
         ]. However, IQ may vary from mild to severe. Males with incomplete methylation of
         <em>
          FMR1
         </em>
         may have IQ in the borderline or low-normal range. Adult females with the full mutation usually have IQ in the normal or mild intellectual disability range. (See
         <a class="medical medical_review" href="/z/d/html/6172.html" rel="external">
          "Intellectual disability (ID) in children: Clinical features, evaluation, and diagnosis"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H18">
         <span class="h1">
          RESOURCES
         </span>
         <span class="headingEndMark">
          —
         </span>
         Internet-based resources for health care providers, patients, and parents/caregivers of with FXS include [
         <a href="#rid63">
          63
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Ffragilex.org%2F&amp;token=T5M9GKYlNl%2BZvkR9N5GxcphyL9KBPQKWKx8XOK6A184%3D&amp;TOPIC_ID=2925" target="_blank">
          The National Fragile X Foundation
         </a>
         (includes a section on FXS resources by age group)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.fraxa.org%2F&amp;token=DzPMsBhauzgvZzN%2FvOiltVNFM82Ee2OPlnJpQ%2B0J%2F0c%3D&amp;TOPIC_ID=2925" target="_blank">
          FRAXA Research Foundation
         </a>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.nichd.nih.gov%2Fhealth%2Ftopics%2Ffragilex&amp;token=lblfowwGB6QwC91WNuiIfyvNJsdpJlnlWJNrnQcYrRXNy87fMxer7pSvGZ0X8hHdkwMP7mNF0b5AbpdCXLNR%2FQ%3D%3D&amp;TOPIC_ID=2925" target="_blank">
          The National Institute of Child Health and Human Development
         </a>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fgtr%2F&amp;token=wEsKVFvqlKzpT%2BqOtddW%2Fy3%2BLj0shalBW%2BL1ZyL4tryNPgji1PaJ6Kbd%2Fo1hE9A6&amp;TOPIC_ID=2925" target="_blank">
          Genetic Testing Registry (GTR)
         </a>
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H530464074">
         <span class="h1">
          SOCIETY GUIDELINE LINKS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See
         <a class="medical medical_society_guidelines" href="/z/d/html/118568.html" rel="external">
          "Society guideline links: Fragile X syndrome"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H436421699">
         <span class="h1">
          INFORMATION FOR PATIENTS
         </span>
         <span class="headingEndMark">
          —
         </span>
         UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5
         <sup>
          th
         </sup>
         to 6
         <sup>
          th
         </sup>
         grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10
         <sup>
          th
         </sup>
         to 12
         <sup>
          th
         </sup>
         grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.
        </p>
        <p>
         Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Basics topic (see
         <a class="medical medical_basics" href="/z/d/html/87575.html" rel="external">
          "Patient education: Fragile X syndrome (The Basics)"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H19">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Management overview
         </strong>
         –
         <strong>
         </strong>
         The management of children and adolescents with fragile X syndrome (FXS) is individualized according to the child's cognitive and behavioral symptoms, as well as strengths and weaknesses. Interventions may include individualized education programs, speech and language therapy, occupational therapy, behavior therapy, and pharmacotherapy. (See
         <a class="local">
          'Introduction'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Genetic counseling
         </strong>
         – Families of persons with FXS should be referred to a geneticist or genetic counselor for a detailed discussion of the inheritance of the fragile X messenger ribonucleoprotein 1 (
         <em>
          FMR1
         </em>
         ) mutation and testing of other family members. (See
         <a class="local">
          'Genetic counseling'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Multidisciplinary assessment
         </strong>
         – Following initial diagnosis of FXS, children and adolescents should undergo a multidisciplinary evaluation for educational planning, assessment of behavioral and emotional needs, and associated medical problems (eg, gastroesophageal reflux, hypotonia, joint laxity, mitral valve prolapse, seizures, strabismus, recurrent otitis media, scoliosis). (See
         <a class="local">
          'Evaluation to determine extent of disease'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Development and education
         </strong>
         – Children and adolescents with FXS usually have special educational needs and should be referred for early developmental stimulation/early intervention and special educational programs. (See
         <a class="local">
          'Developmental and educational interventions'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Neuropsychiatric management
         </strong>
         – Behavioral interventions may be effective in promoting coping skills and reducing problematic behaviors (eg, aggression, stereotypic behaviors, self-injury). Psychopharmacologic intervention is individualized according to symptoms (eg, inattention, hyperactivity, anxiety, mood instability) and must be closely monitored. (See
         <a class="local">
          'Behavioral interventions'
         </a>
         above and
         <a class="local">
          'Pharmacotherapy'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Health supervision
         </strong>
         – Health supervision of children with FXS involves surveillance for a number of associated medical problems, including flat feet, hyperextensible joints, inguinal hernia, gastroesophageal reflux, mitral valve prolapse, recurrent otitis media, refractive errors, strabismus, nystagmus, seizures, scoliosis, depression, and anxiety. (See
         <a class="local">
          'Surveillance'
         </a>
         above.)
        </p>
        <p>
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li class="breakAll">
          Saul RA, Tarleton JC. FMR1-related disorders. GeneReviews. www.ncbi.nlm.nih.gov/bookshelf/br.fcgi?book=gene&amp;part=fragilex (Accessed on December 31, 2009).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hersh JH, Saul RA, Committee on Genetics. Health supervision for children with fragile X syndrome. Pediatrics 2011; 127:994.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Garber KB, Visootsak J, Warren ST. Fragile X syndrome. Eur J Hum Genet 2008; 16:666.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Berry-Kravis E, Potanos K. Psychopharmacology in fragile X syndrome--present and future. Ment Retard Dev Disabil Res Rev 2004; 10:42.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Finucane B, Abrams L, Cronister A, et al. Genetic counseling and testing for FMR1 gene mutations: practice guidelines of the national society of genetic counselors. J Genet Couns 2012; 21:752.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Health supervision for children with fragile X syndrome. American Academy of Pediatrics Committee on Genetics. Pediatrics 1996; 98:297.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Visootsak J, Warren ST, Anido A, Graham JM Jr. Fragile X syndrome: an update and review for the primary pediatrician. Clin Pediatr (Phila) 2005; 44:371.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hoffmann A. Communication in fragile X syndrome: Patterns and implications for assessment and intervention. Front Psychol 2022; 13:929379.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hessl D, Schweitzer JB, Nguyen DV, et al. Cognitive training for children and adolescents with fragile X syndrome: a randomized controlled trial of Cogmed. J Neurodev Disord 2019; 11:4.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Weiskop S, Richdale A, Matthews J. Behavioural treatment to reduce sleep problems in children with autism or fragile X syndrome. Dev Med Child Neurol 2005; 47:94.
          </a>
         </li>
         <li class="breakAll">
          Hills-Epstein J, Riley K, Sobesky W. The treatment of emotional and behavioral problems. In: Fragile X syndrome: Diagnosis, treatment, and research, 3rd ed, Hagerman RJ, Hagerman PJ (Eds), Johns Hopkins University Press, Baltimore 2002. p.339.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Acero-Garcés DO, Saldarriaga W, Cabal-Herrera AM, et al. Fragile X Syndrome in children. Colomb Med (Cali) 2023; 54:e4005089.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Reiss AL, Hall SS. Fragile X syndrome: assessment and treatment implications. Child Adolesc Psychiatr Clin N Am 2007; 16:663.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Durand VM, Carr EG. Social influences on "self-stimulatory" behavior: analysis and treatment application. J Appl Behav Anal 1987; 20:119.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Iwata BA, Pace GM, Dorsey MF, et al. The functions of self-injurious behavior: an experimental-epidemiological analysis. J Appl Behav Anal 1994; 27:215.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hanley GP, Iwata BA, McCord BE. Functional analysis of problem behavior: a review. J Appl Behav Anal 2003; 36:147.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Restivo L, Ferrari F, Passino E, et al. Enriched environment promotes behavioral and morphological recovery in a mouse model for the fragile X syndrome. Proc Natl Acad Sci U S A 2005; 102:11557.
          </a>
         </li>
         <li class="breakAll">
          Braden ML. Education. In: Children with fragile X syndrome: A parent's guide, Woodbine House, Bethesda 2000. p.243.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hagerman RJ, Murphy MA, Wittenberger MD. A controlled trial of stimulant medication in children with the fragile X syndrome. Am J Med Genet 1988; 30:377.
          </a>
         </li>
         <li class="breakAll">
          Erickson CA, Stigler KA, Posey DJ, MCDougle CJ. Managing maladaptive behaviors in fragile X patients. J Fam Practice (on-line) 2006 www.jfponline.com/Pages.asp?AID=4443 (Accessed on December 22, 2009).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hagerman RJ, Riddle JE, Roberts LS, et al. Survey of the efficacy of clonidine in fragile X syndrome. Dev Brain Dysfunct 1995; 8:336.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hagerman RJ, Fulton MJ, Leaman A, et al. A survey of fluoxetine therapy in fragile X syndrome. Dev Brain Dysfunct 1994; 7:155.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           McCracken JT, McGough J, Shah B, et al. Risperidone in children with autism and serious behavioral problems. N Engl J Med 2002; 347:314.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Shea S, Turgay A, Carroll A, et al. Risperidone in the treatment of disruptive behavioral symptoms in children with autistic and other pervasive developmental disorders. Pediatrics 2004; 114:e634.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nagaraj R, Singhi P, Malhi P. Risperidone in children with autism: randomized, placebo-controlled, double-blind study. J Child Neurol 2006; 21:450.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Correll CU, Manu P, Olshanskiy V, et al. Cardiometabolic risk of second-generation antipsychotic medications during first-time use in children and adolescents. JAMA 2009; 302:1765.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hollander E, Chaplin W, Soorya L, et al. Divalproex sodium vs placebo for the treatment of irritability in children and adolescents with autism spectrum disorders. Neuropsychopharmacology 2010; 35:990.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Johnson D, Clark C, Hagerman R. Targeted Treatments for Fragile X Syndrome. Adv Neurobiol 2023; 30:225.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bear MF, Huber KM, Warren ST. The mGluR theory of fragile X mental retardation. Trends Neurosci 2004; 27:370.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Spooren WP, Vassout A, Neijt HC, et al. Anxiolytic-like effects of the prototypical metabotropic glutamate receptor 5 antagonist 2-methyl-6-(phenylethynyl)pyridine in rodents. J Pharmacol Exp Ther 2000; 295:1267.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tatarczyńska E, Klodzińska A, Chojnacka-Wójcik E, et al. Potential anxiolytic- and antidepressant-like effects of MPEP, a potent, selective and systemically active mGlu5 receptor antagonist. Br J Pharmacol 2001; 132:1423.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Michalon A, Sidorov M, Ballard TM, et al. Chronic pharmacological mGlu5 inhibition corrects fragile X in adult mice. Neuron 2012; 74:49.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jacquemont S, Curie A, des Portes V, et al. Epigenetic modification of the FMR1 gene in fragile X syndrome is associated with differential response to the mGluR5 antagonist AFQ056. Sci Transl Med 2011; 3:64ra1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hagerman R, Jacquemont S, Berry-Kravis E, et al. Mavoglurant in Fragile X Syndrome: Results of two open-label, extension trials in adults and adolescents. Sci Rep 2018; 8:16970.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Berry-Kravis E, Abbeduto L, Hagerman R, et al. Effects of AFQ056 on language learning in fragile X syndrome. J Clin Invest 2023.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Berry-Kravis E, Sumis A, Hervey C, et al. Open-label treatment trial of lithium to target the underlying defect in fragile X syndrome. J Dev Behav Pediatr 2008; 29:293.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bilousova TV, Dansie L, Ngo M, et al. Minocycline promotes dendritic spine maturation and improves behavioural performance in the fragile X mouse model. J Med Genet 2009; 46:94.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Utari A, Chonchaiya W, Rivera SM, et al. Side effects of minocycline treatment in patients with fragile X syndrome and exploration of outcome measures. Am J Intellect Dev Disabil 2010; 115:433.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Paribello C, Tao L, Folino A, et al. Open-label add-on treatment trial of minocycline in fragile X syndrome. BMC Neurol 2010; 10:91.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Leigh MJ, Nguyen DV, Mu Y, et al. A randomized double-blind, placebo-controlled trial of minocycline in children and adolescents with fragile x syndrome. J Dev Behav Pediatr 2013; 34:147.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Champigny C, Morin-Parent F, Bellehumeur-Lefebvre L, et al. Combining Lovastatin and Minocycline for the Treatment of Fragile X Syndrome: Results From the LovaMiX Clinical Trial. Front Psychiatry 2021; 12:762967.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chao HT, Chen H, Samaco RC, et al. Dysfunction in GABA signalling mediates autism-like stereotypies and Rett syndrome phenotypes. Nature 2010; 468:263.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Berry-Kravis EM, Hessl D, Rathmell B, et al. Effects of STX209 (arbaclofen) on neurobehavioral function in children and adults with fragile X syndrome: a randomized, controlled, phase 2 trial. Sci Transl Med 2012; 4:152ra127.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Berry-Kravis E, Hagerman R, Visootsak J, et al. Arbaclofen in fragile X syndrome: results of phase 3 trials. J Neurodev Disord 2017; 9:3.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lemonnier E, Robin G, Degrez C, et al. Treating Fragile X syndrome with the diuretic bumetanide: a case report. Acta Paediatr 2013; 102:e288.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pomponi MG, Neri G. Butyrate and acetyl-carnitine inhibit the cytogenetic expression of the fragile X in vitro. Am J Med Genet 1994; 51:447.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rueda JR, Guillén V, Ballesteros J, et al. L-acetylcarnitine for treating fragile X syndrome. Cochrane Database Syst Rev 2015; :CD010012.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Berry-Kravis E, Krause SE, Block SS, et al. Effect of CX516, an AMPA-modulating compound, on cognition and behavior in fragile X syndrome: a controlled trial. J Child Adolesc Psychopharmacol 2006; 16:525.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Busquets-Garcia A, Gomis-González M, Guegan T, et al. Targeting the endocannabinoid system in the treatment of fragile X syndrome. Nat Med 2013; 19:603.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Berry-Kravis E, Hagerman R, Budimirovic D, et al. A randomized, controlled trial of ZYN002 cannabidiol transdermal gel in children and adolescents with fragile X syndrome (CONNECT-FX). J Neurodev Disord 2022; 14:56.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sharma A, Hoeffer CA, Takayasu Y, et al. Dysregulation of mTOR signaling in fragile X syndrome. J Neurosci 2010; 30:694.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Liu XS, Wu H, Krzisch M, et al. Rescue of Fragile X Syndrome Neurons by DNA Methylation Editing of the FMR1 Gene. Cell 2018; 172:979.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Xie N, Gong H, Suhl JA, et al. Reactivation of FMR1 by CRISPR/Cas9-Mediated Deletion of the Expanded CGG-Repeat of the Fragile X Chromosome. PLoS One 2016; 11:e0165499.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lee HG, Imaichi S, Kraeutler E, et al. Site-specific R-loops induce CGG repeat contraction and fragile X gene reactivation. Cell 2023; 186:2593.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Shah S, Sharp KJ, Raju Ponny S, et al. Antisense oligonucleotide rescue of CGG expansion-dependent FMR1 mis-splicing in fragile X syndrome restores FMRP. Proc Natl Acad Sci U S A 2023; 120:e2302534120.
          </a>
         </li>
         <li class="breakAll">
          Wilson GN, Cooley WC. The fragile X syndrome. In: Preventive management of children with congenital anomalies and syndromes, Cambridge University Press, Cambridge, United Kingdom 2000. p.175.
         </li>
         <li class="breakAll">
          Hagerman R. Fragile X syndrome. In: The Zuckerman Parker Handbook of Developmental and Behavioral Pediatrics for Primary Care, 3rd ed, Augustyn M, Zuckerman B, Caronna EB (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2011. p.218.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Davids JR, Hagerman RJ, Eilert RE. Orthopaedic aspects of fragile-X syndrome. J Bone Joint Surg Am 1990; 72:889.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hagerman RJ, Altshul-Stark D, McBogg P. Recurrent otitis media in the fragile X syndrome. Am J Dis Child 1987; 141:184.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hagerman PJ, Stafstrom CE. Origins of epilepsy in fragile X syndrome. Epilepsy Curr 2009; 9:108.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Berry-Kravis E. Epilepsy in fragile X syndrome. Dev Med Child Neurol 2002; 44:724.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Musumeci SA, Hagerman RJ, Ferri R, et al. Epilepsy and EEG findings in males with fragile X syndrome. Epilepsia 1999; 40:1092.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           McConkie-Rosell A, Finucane B, Cronister A, et al. Genetic counseling for fragile x syndrome: updated recommendations of the national society of genetic counselors. J Genet Couns 2005; 14:249.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Merenstein SA, Sobesky WE, Taylor AK, et al. Molecular-clinical correlations in males with an expanded FMR1 mutation. Am J Med Genet 1996; 64:388.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 2925 Version 26.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="www.ncbi.nlm.nih.gov/bookshelf/br.fcgi?book=gene&amp;part=fragilex" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : Saul RA, Tarleton JC. FMR1-related disorders. GeneReviews. www.ncbi.nlm.nih.gov/bookshelf/br.fcgi?book=gene&amp;part=fragilex (Accessed on December 31, 2009).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21518720" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : Health supervision for children with fragile X syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18398441" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Fragile X syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14994287" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Psychopharmacology in fragile X syndrome--present and future.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22797890" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Genetic counseling and testing for FMR1 gene mutations: practice guidelines of the national society of genetic counselors.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8692636" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Health supervision for children with fragile X syndrome. American Academy of Pediatrics Committee on Genetics.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15965543" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Fragile X syndrome: an update and review for the primary pediatrician.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/36619013" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Communication in fragile X syndrome: Patterns and implications for assessment and intervention.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30982467" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Cognitive training for children and adolescents with fragile X syndrome: a randomized controlled trial of Cogmed.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15707232" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Behavioural treatment to reduce sleep problems in children with autism or fragile X syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15707232" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Behavioural treatment to reduce sleep problems in children with autism or fragile X syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/37664646" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Fragile X Syndrome in children.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17562585" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Fragile X syndrome: assessment and treatment implications.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3610892" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Social influences on "self-stimulatory" behavior: analysis and treatment application.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8063623" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : The functions of self-injurious behavior: an experimental-epidemiological analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12858983" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Functional analysis of problem behavior: a review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16076950" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Enriched environment promotes behavioral and morphological recovery in a mouse model for the fragile X syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16076950" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Enriched environment promotes behavioral and morphological recovery in a mouse model for the fragile X syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3052064" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : A controlled trial of stimulant medication in children with the fragile X syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3052064" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : A controlled trial of stimulant medication in children with the fragile X syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Survey of the efficacy of clonidine in fragile X syndrome
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : A survey of fluoxetine therapy in fragile X syndrome
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12151468" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Risperidone in children with autism and serious behavioral problems.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15492353" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Risperidone in the treatment of disruptive behavioral symptoms in children with autistic and other pervasive developmental disorders.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16948927" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Risperidone in children with autism: randomized, placebo-controlled, double-blind study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19861668" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Cardiometabolic risk of second-generation antipsychotic medications during first-time use in children and adolescents.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20010551" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Divalproex sodium vs placebo for the treatment of irritability in children and adolescents with autism spectrum disorders.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/36928853" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Targeted Treatments for Fragile X Syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15219735" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : The mGluR theory of fragile X mental retardation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11082464" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : Anxiolytic-like effects of the prototypical metabotropic glutamate receptor 5 antagonist 2-methyl-6-(phenylethynyl)pyridine in rodents.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11264235" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Potential anxiolytic- and antidepressant-like effects of MPEP, a potent, selective and systemically active mGlu5 receptor antagonist.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22500629" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : Chronic pharmacological mGlu5 inhibition corrects fragile X in adult mice.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21209411" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : Epigenetic modification of the FMR1 gene in fragile X syndrome is associated with differential response to the mGluR5 antagonist AFQ056.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30451888" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Mavoglurant in Fragile X Syndrome: Results of two open-label, extension trials in adults and adolescents.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/37651202" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : Effects of AFQ056 on language learning in fragile X syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18698192" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : Open-label treatment trial of lithium to target the underlying defect in fragile X syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18835858" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : Minocycline promotes dendritic spine maturation and improves behavioural performance in the fragile X mouse model.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20687826" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : Side effects of minocycline treatment in patients with fragile X syndrome and exploration of outcome measures.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20937127" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : Open-label add-on treatment trial of minocycline in fragile X syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23572165" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : A randomized double-blind, placebo-controlled trial of minocycline in children and adolescents with fragile x syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35058813" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : Combining Lovastatin and Minocycline for the Treatment of Fragile X Syndrome: Results From the LovaMiX Clinical Trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21068835" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : Dysfunction in GABA signalling mediates autism-like stereotypies and Rett syndrome phenotypes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22993294" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : Effects of STX209 (arbaclofen) on neurobehavioral function in children and adults with fragile X syndrome: a randomized, controlled, phase 2 trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28616094" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : Arbaclofen in fragile X syndrome: results of phase 3 trials.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23647528" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : Treating Fragile X syndrome with the diuretic bumetanide: a case report.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7943015" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : Butyrate and acetyl-carnitine inhibit the cytogenetic expression of the fragile X in vitro.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25985235" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : L-acetylcarnitine for treating fragile X syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17069542" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : Effect of CX516, an AMPA-modulating compound, on cognition and behavior in fragile X syndrome: a controlled trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23542787" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : Targeting the endocannabinoid system in the treatment of fragile X syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/36434514" id="rid49" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          50 : A randomized, controlled trial of ZYN002 cannabidiol transdermal gel in children and adolescents with fragile X syndrome (CONNECT-FX).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20071534" id="rid50" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          51 : Dysregulation of mTOR signaling in fragile X syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29456084" id="rid51" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          52 : Rescue of Fragile X Syndrome Neurons by DNA Methylation Editing of the FMR1 Gene.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27768763" id="rid52" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          53 : Reactivation of FMR1 by CRISPR/Cas9-Mediated Deletion of the Expanded CGG-Repeat of the Fragile X Chromosome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/37209683" id="rid53" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          54 : Site-specific R-loops induce CGG repeat contraction and fragile X gene reactivation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/37364131" id="rid54" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          55 : Antisense oligonucleotide rescue of CGG expansion-dependent FMR1 mis-splicing in fragile X syndrome restores FMRP.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/37364131" id="rid55" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          56 : Antisense oligonucleotide rescue of CGG expansion-dependent FMR1 mis-splicing in fragile X syndrome restores FMRP.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/37364131" id="rid56" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          57 : Antisense oligonucleotide rescue of CGG expansion-dependent FMR1 mis-splicing in fragile X syndrome restores FMRP.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2195034" id="rid57" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          58 : Orthopaedic aspects of fragile-X syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3812386" id="rid58" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          59 : Recurrent otitis media in the fragile X syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19693328" id="rid59" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          60 : Origins of epilepsy in fragile X syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12418611" id="rid60" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          61 : Epilepsy in fragile X syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10448821" id="rid61" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          62 : Epilepsy and EEG findings in males with fragile X syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16047089" id="rid62" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          63 : Genetic counseling for fragile x syndrome: updated recommendations of the national society of genetic counselors.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8844089" id="rid63" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          64 : Molecular-clinical correlations in males with an expanded FMR1 mutation.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
